New Orleans, LA | May 7-10
ISCT Annual Meetings are the undisputed heavyweight champions of the cell and gene therapy world. Every year, this global gathering unites the brightest minds – experts who are relentlessly pushing the boundaries of clinical translation in this field. This year ISCT takes place May 7-10 at the Ernest N. Morial Convention Center.
Visit the conference’s website to learn more about the event.
Technical Sessions
Registration for this session is not required, but seating is limited. Arrive early and grab that seat!
Speakers:
Nick Randall
Bioprocessing Product Manager
908 Devices
Brian Philip
Principal Scientist
NIBRT
IIMPROVING CELL THERAPY MANUFACTURING ROBUSTNESS WITH REAL-TIME ANALYTICS
Wednesday, May 7
7:00 AM – 8:00 AM
Rivergate Room, Level One
CAR-T manufacturing has seen improvements in the last few years with increasing use of automated and closed systems. However, processes still lack robustness due to offline analytics and the lack of process understanding. On-line monitoring of key process parameters, such as glucose and lactate, enables deeper process understanding allowing for more robust and controlled processes. This, in turn, leads to more reliable and cost-effective manufacturing, ultimately helping to make therapies more accessible to patients in need. Here we present a case study where T-cells and CAR-T cells were expanded in the Xuri Cell Expansion System (Cytiva), in culture media variant with online monitoring of glucose and lactate using the MAVEN device (908 Devices/Repligen).
Session Objectives:
· Optimized Manufacturing: CAR-T cells were produced using the Xuri™ Cell Expansion System (Cytiva), ensuring a controlled environment for cell growth.
· Real-Time Monitoring: The MAVEN device (908 Devices) enabled automated continuous tracking of glucose and lactate levels, optimizing cell culture conditions.
· Comprehensive Evaluation: Flow cytometry and cytotoxicity assays were used to assess the qualitative impact of glucose variations on CAR-T cells.
· Enhanced Cell Potency: Real-time monitoring of key parameters contributed to the development of robust and potent CAR-T cells.
· Future Implications: Automated bioreactor systems and online analytics are critical for scaling CAR-T therapies cost-effectively to a broader patient population.
908 Devices Poster at the Conference
Poster Networking Session 2
Thursday, May 8
6:00-7:30PM
IMPROVING CELL THERAPY MANUFACTURING ROBUSTNESS WITH REAL-TIME ANALYTICS
Presented by: Nick Randall
Poster ID: #-846
Ensuring Effectiveness and Consistency
A well-characterized and controlled production process is crucial for effectiveness of cell therapy and necessitates integration of Process Analytical Technology (PAT) solutions with automated cell therapy manufacturing systems. MAVEN and MAVERICK easily integrate with cell therapy manufacturing systems and deliver continuous monitoring and control of critical process parameters (CPPs) such as glucose, lactate and total biomass, enhancing process understanding, ensuring robustness and reducing human intervention. With REBEL amino acids concentrations in the media can be frequently monitored during cell expansion processes to ensure that any variations in cell growth and health were not due to unknown changes in expected media formulation.